iLCT Pipeline project: Theracurmin
This preclinical study aims to assess whether Theracurmin – a formulation of curcumin – can slow progression in models of Parkinson’s. Contents About the study Curcumin, a compound found in turmeric, is well known for its antioxidant and anti-inflammatory properties; because of this, researchers have...
EJS ACT-PD: The Edmond J Safra Accelerating Clinical Trials for Parkinson’s trial
EJS ACT-PD is an initiative to transform the way clinical trials are conducted in the UK. As a multi-arm, multi-stage (MAMS) trial platform, EJS ACT-PD will evaluate several potentially disease-modifying treatments in parallel against a shared placebo (dummy drug) group. Contents About the study Led...
Rifabutin for Parkinson’s
This preclinical study is assessing whether rifabutin, an antibiotic, can protect nerve cells (neurons) by reducing levels of alpha-synuclein. Contents About the study Dr Lorraine Kalia at University Health Network, Toronto is investigating the antibiotic rifabutin as a potentially disease-modifying drug in laboratory models of...
iLCT Pipeline Project: Carnosic acid
This preclinical project aims to determine whether carnosic acid – a compound found in rosemary and sage – can slow progression in models of Parkinson’s. Contents About the study In this study, Dr Sinead A. O’Sullivan and Prof. Donato A. Di Monte at the German...
AZA-PD: Azathioprine for Parkinson’s
AZA-PD was a phase 2 clinical trial of azathioprine – an immunosuppressant medication – to evaluate its safety and ability to lower neuroinflammation in people with Parkinson’s. Contents About the study Dr Caroline Williams-Gray at the University of Cambridge led a phase 2 clinical trial...
Screening iLCT-evaluated drugs
This preclinical study will compare the effectiveness of 100 drugs previously evaluated by our iLCT committee to better prioritise the most promising compounds for clinical trial. Contents About the study Prof Heather Mortiboys at the University of Sheffield will be conducting a two-year pre-clinical study...
DAPA-PD: Dapansutrile for Parkinson’s
DAPA-PD is a phase 2 clinical trial of dapansutrile – a novel anti-inflammatory drug – to determine whether it may be able to slow Parkinson’s progression. Contents About the study Led by Dr Caroline Williams-Gray at Cambridge University, DAPA-PD will recruit 36 people with Parkinson’s....
iLCT Pipeline Project: Probucol and chlorogenic acid
This preclinical study aims to gather evidence on whether two compounds – probucol and chlorogenic acid – have a neuroprotective effect in models of Parkinson’s. Contents About the study Both probucol and chlorogenic acid have been evaluated by the International Linked Clinical Trials (iLCT) committee,...
Exenatide-PD3: Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...
ASPro-PD: Ambroxol and Parkinson’s
ASPro-PD, or Ambroxol to Slow Progression in Parkinson’s, is a phase 3 clinical trial looking to assess whether ambroxol, a cough medicine, can slow or stop the progression of Parkinson’s motor symptoms. Contents About the study Led by Professor Anthony Schapira at University College London...